Hill Emily Luisa sold $132K of REPL

Hill Emily Luisa (Chief Financial Officer) sold 9,256 shares of Replimune Group, Inc. (REPL) at $14.28 ($0.13M total) on 2026-08-17.

Original reporting
SEC EDGAR · Hill Emily Luisa
Published Aug 19, 2026, 10:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REPL
Neutral
medium confidence
Mentioned
$REPL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REPLNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock materially, but it adds to the flow of insider activity data.

02

Market read

A routine insider sale with limited trading relevance; investors may note but unlikely to act.

03

What to watch

Potential upcoming corporate actions or personal tax planning may have driven the sale.

Relevance 4/10Novelty 4/10Timing: filed after market close on 2026-08-19

Background

Form 4 filings disclose insider transactions; CFO sales are monitored for potential signals.

Company-level read

Ticker impact

$REPLNeutralMedium confidence
Context

CFO Emily Luisa Hill sold 9,256 shares for $132,176, reducing her stake to 215,852 shares.

Expected impact

Minimal short-term price pressure, likely within normal volatility range.

Evidence & confidence

The transaction size is modest relative to market cap and typical insider activity, so any price effect is expected to be limited.

Market effects

No immediate sector-wide impact; biotech sector remains driven by broader pipeline news.

Limited to US markets where REPL trades; no broader regional effect.

Insignificant on a global scale.

Counterpoint

The sale could be a routine liquidity move rather than a negative signal.

Key entities

  • Replimune Group, Inc.

    Biotech firm focused on cancer immunotherapy, ticker REPL.

  • Emily Luisa Hill

    Chief Financial Officer of Replimune Group, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REPLHigh

Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians

Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.

$REPLMed

Replimune (REPL) Q2 2027 Earnings Call Transcript

Replimune (REPL) reported Q2 2027 earnings, highlighting the commercial launch of TUDRIQEV. The company noted strong physician interest and rapid adoption, with over 15 institutions prescribing the drug in less than 20 business days. Replimune reported a net loss of $57.1 million for the quarter, with $307.8 million in cash reserves. The company expects to report first product revenue in Q3 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$REPLMed

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.